|
|Section2= |Section3= }} NVP-AUY922 is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis〔(【引用サイトリンク】 Structure-based design of cancer therapeutics )〕 and licensed to Novartis.〔(【引用サイトリンク】 AUY922 )〕 It is currently in Phase II clinical trials.〔(【引用サイトリンク】 Small caps: Vernalis drug fillip )〕 NVP-AUY922 is an inhibitor of heat shock protein 90 (Hsp90),〔 which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. NVP-AUY922 has shown promising activity in preclinical testing against several different tumor types. ==See also== * Hsp90 inhibitors 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「NVP-AUY922」の詳細全文を読む スポンサード リンク
|